Menopause and HRT

Urinary Incontinence Drug May Reduce Frequency of Hot Flashes

By December 10, 2018

Oxybutynin, an anticholinergic used to treat urinary incontinence, may provide breast cancer survivors with an alternative treatment option for hot flashes, according to new research.

Menopausal Hormone Therapy May Reduce Carpal Tunnel Syndrome Risk

By December 05, 2018

To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.

Bijuva Approved for Moderate to Severe Vasomotor Symptoms Due to Menopause

By October 29, 2018

Approval from the Food and Drug Administration (FDA) was supported by the Phase 3 Replenish trial which evaluated the safety and efficacy of Bijuva in generally healthy, postmenopausal women with a uterus for the treatment of moderate to severe hot flashes.

FDA Approves Diagnostic Test to Help Determine Menopausal Status

By October 25, 2018

The FDA's marketing approval was supported by data from 690 women (aged 42 to 62 years) who were enrolled in the Study of Women's Health Across the Nation.

Imvexxy Now Available in 4mcg Dosage Strength for Dyspareunia Due to Menopause

By September 13, 2018

According to the Imvexxy prescribing information, women should generally be started at the 4mcg dosage strength with dosage adjustment guided by clinical response.

Guidelines for Managing Perimenopausal Depression Now Available

By September 05, 2018

The 5 topics addressed by the 11-member expert panel include epidemiology, clinical presentation, therapeutic effects of antidepressants, effects of hormone therapy, and the effectiveness of other therapies (eg, psychotherapy, exercise, natural health products).

FDA: Energy-Based Devices Should Not Be Used for Vaginal "Rejuvenation"

By July 31, 2018

The Agency has become aware of some manufacturers marketing these devices for vaginal "rejuvenation" or vaginal cosmetic procedures.

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

By July 13, 2018

Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.

Reproductive Dysfunction Risk in Women Taking Long-Term Pain Meds

July 10, 2018

Women prescribed long- vs short-term opioids for chronic musculoskeletal pain may be at increased risk for menopause and abnormal menstruation.

Imvexxy Approved for Moderate to Severe Dyspareunia Due to Menopause

By May 30, 2018

The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12.

Anxiety Levels Tied to Bone Mineral Density Post-Menopause

May 14, 2018

There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.

Low-Dose Vaginal Estradiol Improves Menopause-Linked QOL

May 10, 2018

The MENQOL sexual function domain had a significant between-group difference favoring vaginal estradiol (−0.4 at 12 weeks); significant differences were not seen for the other domains.

Older Adults Agree Sex Is Important Part of Relationships

May 03, 2018

Forty percent indicated that they were currently sexually active; sexual activity decreased with age. More than half (54%) of respondents agreed that sex is important to their overall quality of life, with men more likely to agree than women (70 versus 40%).

Certain Foods May Affect Timing of Menopause

May 01, 2018

"Our results suggest that some food groups (oily fish, fresh legumes, refined pasta and rice) and specific nutrients are individually predictive of age at natural menopause," the authors write.

Alcohol Consumption Has Moderate Association With PMS

April 25, 2018

This association was most pronounced with heavy drinking (odds ratio, 1.79). It is plausible there is a reverse causation process, in which PMS-affected women use alcohol to mitigate the effect of the syndrome.

Menopausal Hormone Therapy Linked to Reduced Abdominal Fat

March 28, 2018

No residual effect for past users, including early discontinuers of menopause hormone treatment

Impact of Menopausal Hormone Tx on Cognition Assessed 3-Years Post Treatment

March 22, 2018

The longitudinal decline in dorsolateral prefrontal cortex volumes was less in the tE2 group compared with the placebo group. In the menopausal hormone therapy groups, the rates of global cognitive change did not differ from that of the placebo group.

Efficacy of Moisturizer, Estradiol Tablets Examined in Treating Vulvovaginal Symptoms

March 20, 2018

Similar reductions were seen for most bothersome symptom severity for all treatment groups over 12 weeks (estradiol, −1.4; moisturizer, −1.2; and placebo, −1.3).

Abaloparatide Followed by Alendronate Ups BMD in Postmenopausal Women

By March 19, 2018

At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.

FDA Accepts NDA for Bio-Identical Combination Hormone Therapy

By March 09, 2018

TX-001HR is an investigational treatment for moderate-to-severe vasomotor symptoms due to menopause.

Product Defect Leads to Recall of Hormone Replacement Therapy

By March 05, 2018

The recall was initiated due to a manufacturing defect.

Menopausal Hormone Therapy May Aid in Reducing Spine Injury

February 23, 2018

The researchers found that, compared with never-users of HT, continuous users had a mean Cobb angle that was 4.0 degrees less, in minimally-adjusted models (P=0.01); in fully-adjusted models, the correlation was attenuated to 2.8 degrees (P=0.06).

Number of Children, Age at First Birth May Contribute to Higher CVD Risk in Women

January 16, 2018

For CVD, adjusted hazard ratios of 1.16 and 2.30 were seen for hysterectomy without oophorectomy or with previous oophorectomy, respectively.

Drug-Free Supplements Launched for Menopause Symptom Relief

By December 15, 2017

The drug-free supplements also contain varying levels of flax, vitamin B2, vitamin B6, D-biotin, and vitamin D3.

USPSTF Updates Recommendation on Menopausal Hormone Therapy

December 12, 2017

Based on these findings, the USPSTF concluded that for most postmenopausal women with an intact uterus, combined estrogen and progestin had no net benefit for primary prevention of chronic conditions (D recommendation).

Postmenopausal Estradiol May Protect Against Effects of Stress

November 03, 2017

The researchers found that the women assigned to estradiol exhibited blunted cortisol responses to CPT compared with the women in the placebo group (P=0.017) and lesser negative effects of stress on working memory (P=0.048).

CombiPatch, Minivelle Patches No Longer in Shortage

By October 03, 2017

Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.

Hormone Tx During Menopause and Mortality Rate: Is There a Link?

September 13, 2017

The researchers found that during the 18-year follow-up, there were 7,489 deaths (1,088 deaths during the intervention phase and 6,401 deaths during postintervention follow-up).

Non-Hormone Options Recommended for Depletion After Breast CA

August 30, 2017

The researchers recommend that women should not generally be treated with menopausal hormone therapy or tibolone following breast cancer, but should optimize lifestyle.

Licorice Supplements May Put Patients at Risk for Drug Interactions

By August 22, 2017

More women are looking toward alternatives like licorice due to, "concerns about the risk of stroke and breast cancer associated with conventional hormone," said Richard B. van Breemen, PhD, and lead author.